Endoglin is a suitable target for efficient imaging of solid tumors: In vivo evidence in a canine mammary carcinoma model

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2037-2043

  Fonsatti, Ester ^a   Jekunen, Antti P ^b   Kairemo, Kalevi J A ^b   Coral, Sandra ^a   Snellman, Marjatta ^b   Nicotra, Maria Rita ^c   Natali, Pier Giorgio ^d   Altomonte, Maresa ^a   Maio, Michele ^a,e  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF HELSINKI   (Finland)

^c CNR   (Italy)

^d Laboratory of Immunology   (Italy)

^e Advanced Immunotheraphy Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; IODINE 125; MONOCLONAL ANTIBODY; THYMIDINE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; DIAGNOSTIC IMAGING; DOG; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD31; BREAST NEOPLASMS; CELL COUNT; CELL DIVISION; CELL LINE; DISEASE MODELS, ANIMAL; DOGS; ENDOTHELIUM, VASCULAR; FEMALE; GAMMA CAMERAS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; MAMMARY NEOPLASMS, ANIMAL; NEOPLASMS; RECEPTORS, CELL SURFACE; RNA, NEOPLASM; TUMOR CELLS, CULTURED; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0034027107     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Gougos, A., and Letarte, M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J. Immunol., 141: 1925-1933, 1988.
2. Luque, A., Cabanas, C., Raab, U., Letamendia, A., Páez, E., Herreros, L., Sanchez-Madrid, F., and Bernabeu, C. The use of recombinant vaccinia virus to generate monoclonal antibodies against the cell-surface glycoprotein endoglin. FEBS Lett., 413: 265-268, 1997.
3. Barbara, N. P., Wrana, J. L., and Letarte, M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J. Biol. Chem., 274: 584-594, 1999.
4. Li, D. Y., Sorensen, L. K., Brooke, B. S., Urness, L. D., Davis, E. C., Taylor, D. G., Boak, B. B., and Wendel, D. P. Defective angiogenesis in mice lacking endoglin. Science (Washington DC), 284: 1534-1537, 1999.
5. McAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A., Jackson, C. E., Helmbold, E. A., Markel, D. S., McKinnon, W. C., Murrell, J., McCormick, M. K., Pericak-Vance, M. A., Heutink, P., Oostra, B. A., Haitjema, T., Westerman, C. J. J., Porteous, M. E., Guttmacher, A. E., Letarte, M., and Marchuk, D. A. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet., 8: 345-351, 1994.
6. Rokhlin, O. W., Cohen, M. B., Kubagawa, H., Letarte, M., and Cooper, M. D. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J. Immunol., 154: 4456-4465, 1995.
7. Robledo, M. M., Hidalgo, A., Lastres, P., Arroyo, A. G., Bernabeu, C., Sanchez-Madrid, F., and Teixido J. Characterization of TGF-β1 binding proteins in human bone marrow stromal cells. Br. J. Haematol., 93: 507-514, 1996.
8. Lastres, P., Bellon, T., Cabañas, C., Sanchez-Madrid, F., Acevedo, A., Gougos, A., Letarte, M., and Bernabeu, C. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur. J. Immunol., 22: 393-397, 1992.
9. Wang, J. M., Kumar, S., Pye, D., van Agthoven, A. J., Krupinski, J., and Hunter, R. D. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer, 54: 363-370, 1993.
10. Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P., Gazdar, A. F., King, S. W., Letarte, M., Vitetta, E. S., and Thorpe, P. E. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res., 1: 1623-1634, 1995.
11. Seon, B. K., Matsuno, F., Haruta, Y., Barcos, M., and Spaulding, B. CD105 Workshop: immunohistochemical detection of CD105 in the vascular endothelium of human malignant and non-malignant tissues. In: T. Kishimoto, H. Kikutani, A. E. G. K. von dem Borne, S. M. Goyert, D. Y. Mason, M. Miyasaka, L. Moretta, K. Okumura, S. Shaw, T. A. Springer, K. Sugamura, and H. Zola (eds.), Leucocyte Typing VI. White Cell Differentiation Antigens, pp. 709-711. New York: Garland Publishing, Inc., 1997.
12. Altomonte, M., Montagner, R., Fonsatti, E., Colizzi, F., Cattarossi, I., Brasoveanu, L. I., Nicotra, M. R., Cattelan, A., Natali, P. G., and Maio, M. Expression and structural features of endoglin (CD105), a transforming growth factor β1, and β3 binding protein, in human melanoma. Br. J. Cancer, 74: 1586-1591, 1996.
13. Henriksen, R., Gobi, A., Wilander, E., Oberg, K., Miyazono, K., and Funa, K. Expression and prognostic significance of TGF-β isotypes, latent TGF-β1 binding protein. TGF-β type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab. Investig., 73: 213-220, 1995.
14. Hobson, B., and Denekamp, J. Endothelial proliferation in tumors and normal tissues: continuous labelling studies. Br. J. Cancer, 49: 405-413, 1984.
15. Herlyn, M. Endothelial cells as targets for tumor therapy. J. Immunother., 22: 185, 1999.
16. Miller, D. W., Graulich, W., Karges, B., Stahl, S., Ernst, M., Ramaswamy, A., Sedlacek, H. H., Muller, R., and Adamkiewicz, J. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer, 81: 568-572, 1999.
17. Wang, J. M., Kumar, S., Pye, D., Haboubi, N., and Al-Nakib, L. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J. Natl. Cancer Inst., 86: 386-388, 1994.
18. Bodey, B., Bodey, B., Jr., Siegel, S. E., and Kaiser, H. E. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res., 18: 2701-2710, 1998.
19. Bodey, B., Bodey, B., Jr., Siegel, S. E., and Kaiser, H. E. Overexpression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. Anticancer Res., 18: 3621-3628, 1998.
20. Kumar, S., Ghellal, A., Li, C., Byrne, G., Haboubi, N., Wang, J. M., and Bundred, N. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res., 59: 856-861, 1999.
21. Bouck, N., Stellmach, V., and Hsu, S. C. How tumors become angiogenic. Adv. Cancer Res., 69: 135-174, 1996.
22. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L., McCulloch, P., Pezzella, F., Viale, G., Weidner, N., Harris, A. L., and Dirix, L. Y. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer, 32A: 2474-2484, 1996.
23. Makgoba, M. W., Sanders, M. E., Ginther Luce, G. E., Dustin, M. L., Springer, T. A., and Shaw, S. ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature (Lond.), 331: 86-88, 1988.
24. Fonsatti, E., Altomonte, M., Coral, S., Cattarossi, I., Nicotra, M. R., Gasparollo, A. Natali, P. G., and Maio, M. Tumor-derived interleukin 1α (IL-1α) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells. Br. J. Cancer, 76: 1255-1261, 1997.
25. Brasoveanu, L. I., Fonsatti, E., Visintin, A., Pavlovic, M., Cattarossi, I., Colizzi, F., Gasparollo, A., Coral, S., Horejsi, V., Altomonte, M., and Maio, M. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J. Clin. Investig., 100: 1248-1255, 1997.
26. Maio, M., Pinto, A., Carbone, A., Zagonel, V., Gloghini, A., Marotta, G., Cirillo, D., Colombatti, A., Ferrara, F., Del Vecchio, L., and Ferrone, S. Differential expression of CD54/intercellular-adhesion-molecule-1 in myeloid leukemias and in lympho-proliferative disorders. Blood, 76: 783-790, 1990.
27. Coral, S., Sigalotti, L., Gasparollo, A., Cattarossi, I., Visintin, A., Cattelan, A., Altomonte, M., and Maio, M. Prolonged up-regulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J. Immunother., 22: 16-24, 1999.
28. Fraker, P. J., and Speck, J. C. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem. Biophys. Res. Commun., 80: 849-857, 1978.
29. Mazurov, A. V., Vinogradov, D. V., Kabaeva, N. V., Antonova, G. N., Romanov, Y. A., Vlasik, T. N., Antonov, A. S., and Smirnov, V. N. A monoclonal antibody, VM64, reacts with a 130 kDa glycoprotein common to platelets and endothelial cells: heterogeneity in antibody binding to human aortic endothelial cells. Thromb. Haemostasis, 66: 494-499, 1991.
30. Goldsmith, S. J. Receptor imaging: competitive or complementary to antibody imaging? Semin. Nucl. Med., 2: 85-93, 1997.
31. Park, C. H. The role of radioisotopes in radiation oncology. Semin. Oncol., 24: 639-654, 1997.
32. Buchsbaum, D. J. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res., 55 (Suppl.): 5729s-5732s, 1995.
33. Katzenellenbogen, J. A., Coleman, R. E., Hawkins, R. A., Krohn, K. A., Larson, S. M., Mendelsohn, J., Osborne, C. K., Piwnica-Worms, D., Reba, R. C., Siegel, B. A., Welch, M. J., and Stern, F. Tumor receptor imaging: Proceedings of the National Cancer Institute Workshop, review of current work, and prospective for further investigations. Clin. Cancer Res., 1: 921-932, 1995.
34. 99mTc methoxyisobutylisonitrile in imaging breast cancer. Semin. Nucl. Med., 1: 40-54, 1997.
35. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1989.
36. Burrow, F. J., and Thorpe, P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA, 90: 8996-9000, 1993.
37. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (Washington DC), 275: 547-550, 1997.
38. Ran, S., Gao, B., Duffy, S., Watkins, L., Rote, N., and Thorpe, P. E. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res., 58: 4646-4653, 1998.
39. Seon, B. K., Matsuno, F., Haruta, Y., Kondo, M., and Barcos, M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with anti-human endoglin immunotoxin. Clin. Cancer Res., 3: 1031-1044, 1997.
40. Matsuno, F., Haruta, Y., Kondo, M., Tsai, H., Barcos, M., and Seon, B. K. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new antiendoglin monoclonal antibodies. Clin. Cancer Res., 5: 371-382, 1999.